Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PEOPLE - Changes at Aksys

This article was originally published in Clinica

Executive Summary

Aksys, the Lincolnshire, Illinois haemodialysis products firm, has announced changes to most of its board, effective June 23. The new directors are: Dr Douglass Given (partner and life sciences advisor/investor at merchant bank Bay City Capital); Timothy Mayleben (life science and healthcare company consultant, and director of NightHawk Radiology Holdings and Aastron Biosciences); Gretchen Piller (director of research for asset management firm Torrey Associates); and Leslie Lake (MD of private equity firm Invus Group).

You may also be interested in...



Indoco Counts On Indian Market Bouncing Back

Indoco’s domestic performance picks up pace as the Indian pharma market sees a “bounce back” after a long COVID-induced slump.  The Indian company continues to perform well internationally and grow overall.

‘Ready For Day 1’ – UK MHRA’s Statement Of Intent For Post-Brexit Medtech Regulatory System

The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.

African Platform Eyes $750m Investment

Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.

Topics

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel